Literature DB >> 31366541

Risk Factors Associated With Early Recurrence of Borderline Resectable Pancreatic Ductal Adenocarcinoma After Neoadjuvant Chemoradiation Therapy and Curative Resection.

Nobuhiro Tsuchiya1, Ryusei Matsuyama1, Takashi Murakami1, Yasuhiro Yabushita1, Y U Sawada1, Takafumi Kumamoto1, Itaru Endo2.   

Abstract

BACKGROUND/AIM: To identify risk factors of early recurrence after neoadjuvant chemoradiation therapy (NACRT) and curative pancreatectomy in patients with borderline resectable (BR) pancreatic ductal adenocarcinoma (PDAC). PATIENTS AND METHODS: Sixty-one patients with BR-PDAC who underwent curative resection after NACRT during July 2009-June 2014 were included. Patients were divided into early recurrence (i.e., developed recurrence within 1 year after pancreatectomy; n=30) and late/non-recurrence groups (n=31). The patient characteristics, clinicopathological factors of early recurrence, and survival time were retrospectively compared between groups.
RESULTS: In the univariate analysis, the maximum standardized uptake value (SUVmax), microvascular invasion, and lymph node metastasis were associated with early recurrence. In the multivariate analysis, the pre-NACRT SUVmax and microvascular invasion in the early recurrence group were significantly different from that in the late/non-recurrence group. A pre-NACRT SUVmax >4.1 was an independent predictor of poor recurrence-free and overall survival.
CONCLUSION: SUVmax and microvascular invasion are independent predictors of poor recurrence-free and overall survival after NACRT for BR-PDAC. Although complete pancreatectomy after NACRT was performed, approximately half of the patients had recurrence within 1 year. Copyright
© 2019, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Entities:  

Keywords:  Pancreatectomy; pancreatic ductal carcinoma; positron-emission tomography; recurrence; risk factors

Mesh:

Year:  2019        PMID: 31366541     DOI: 10.21873/anticanres.13615

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  4 in total

1.  Prognostic Significance of Microvascular Invasion in Pancreatic Ductal Adenocarcinoma: A Systematic Review and Meta-Analysis.

Authors:  Huangbao Li; Weiwei Pan; Liu Xu; Dong Yin; Shuqun Cheng; Fengqing Zhao
Journal:  Med Sci Monit       Date:  2021-08-16

2.  Neoadjuvant chemoradiation alters the immune microenvironment in pancreatic ductal adenocarcinoma.

Authors:  Robyn D Gartrell; Thomas Enzler; Pan S Kim; Benjamin T Fullerton; Ladan Fazlollahi; Andrew X Chen; Hanna E Minns; Subha Perni; Stuart P Weisberg; Emanuelle M Rizk; Samuel Wang; Eun Jeong Oh; Xinzheng V Guo; Codruta Chiuzan; Gulam A Manji; Susan E Bates; John Chabot; Beth Schrope; Michael Kluger; Jean Emond; Raul Rabadán; Donna Farber; Helen E Remotti; David P Horowitz; Yvonne M Saenger
Journal:  Oncoimmunology       Date:  2022-05-05       Impact factor: 7.723

3.  Factors Affecting Adenoma Risk Level in Patients with Intestinal Polyp and Association Analysis.

Authors:  Ying Dai; Weimin Chen; Xuanfu Xu; Jianqing Chen; Wenhui Mo; Yiming Chen; Shuqi Xu
Journal:  J Healthc Eng       Date:  2022-01-15       Impact factor: 2.682

4.  Preoperative serum carbohydrate antigen 19-9 levels predict early recurrence after the resection of early-stage pancreatic ductal adenocarcinoma.

Authors:  Sarang Hong; Ki Byung Song; Dae Wook Hwang; Jae Hoon Lee; Woohyung Lee; Eunsung Jun; Jaewoo Kwon; Yejong Park; Seo Young Park; Naru Kim; Dakyum Shin; Hyeyeon Kim; Minkyu Sung; Yunbeom Ryu; Song Cheol Kim
Journal:  World J Gastrointest Surg       Date:  2021-11-27
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.